本帖最后由 老马 于 2013-3-13 13:43 编辑 : y8 T* z4 W; v, _: [# a( o
4 @4 R( ~8 S4 K1 R2 Y/ ?+ O" J健择（吉西他滨）+顺铂+阿瓦斯汀
) D1 t/ A/ }; D Gemzar +Cisplatin + Avastin g% v, P ^; E E% A: H
http://annonc.oxfordjournals.org/content/21/9/1804.full
6 L% E7 m/ y! K* o% ROverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ' b' A& ?, s6 S: C6 Z# N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. s& l% {" i. P) k* z3 w {Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. % f) X1 j# Y! c
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 246)
! { g( d+ `, V+ f
华为网盘附件：0 T% A1 d7 b6 ]* J
【华为网盘】ava.JPG
& P: B5 [$ d; j' I+ I7 R |
显身卡
